| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Sufi Mary Thomas | |
| Levi Arnold | |||
| Jonathan Enders | |||
| P2860 | cites work | The Hallmarks of Cancer | Q221226 |
| Identification of the Hepatocyte Growth Factor Receptor As the c- met Proto-Oncogene Product | Q24310794 | ||
| Regulation of the Met receptor-tyrosine kinase by the protein-tyrosine phosphatase 1B and T-cell phosphatase | Q24316395 | ||
| Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor | Q24321843 | ||
| Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor | Q24322087 | ||
| Heparanase 2 interacts with heparan sulfate with high affinity and inhibits heparanase activity | Q24336040 | ||
| Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors | Q24339620 | ||
| An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice | Q24561588 | ||
| ret transforming gene encodes a fusion protein homologous to tyrosine kinases | Q24628687 | ||
| Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3 | Q24633878 | ||
| An overview of the c-MET signaling pathway | Q24633986 | ||
| Wnt signal transduction pathways | Q24641814 | ||
| Head and neck cancer: causes, prevention and treatment | Q26864179 | ||
| c-MET regulates myoblast motility and myocyte fusion during adult skeletal muscle regeneration | Q27300880 | ||
| Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK) | Q27671432 | ||
| Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival | Q27851502 | ||
| The motogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein | Q28114826 | ||
| Met receptor tyrosine kinase: enhanced signaling through adapter proteins | Q28140219 | ||
| Signaling of hepatocyte growth factor/scatter factor (HGF) to the small GTPase Rap1 via the large docking protein Gab1 and the adapter protein CRKL | Q28141139 | ||
| Hepatocyte growth factor inhibits anoikis in head and neck squamous cell carcinoma cells by activation of ERK and Akt signaling independent of NFkappa B | Q28216726 | ||
| Met, metastasis, motility and more | Q28235183 | ||
| Induction of epithelial tubules by growth factor HGF depends on the STAT pathway | Q28259695 | ||
| Hepatocyte growth factor induces proliferation and morphogenesis in nonparenchymal epithelial liver cells | Q28270220 | ||
| The tyrosine-phosphorylated hepatocyte growth factor/scatter factor receptor associates with phosphatidylinositol 3-kinase | Q28280668 | ||
| Pathways downstream of Shc and Grb2 are required for cell transformation by the tpr-Met oncoprotein | Q28281666 | ||
| A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family | Q28285975 | ||
| Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis | Q28295920 | ||
| Scatter factor/hepatocyte growth factor is essential for liver development | Q28504542 | ||
| Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud | Q28506228 | ||
| The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor | Q48017929 | ||
| Hepatocyte growth factor (HGF/SF) is a muscle-derived survival factor for a subpopulation of embryonic motoneurons | Q48046833 | ||
| Overexpression of the Met/HGF receptor in ovarian cancer. | Q48079353 | ||
| Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas | Q48146638 | ||
| Characterization of the mouse met proto-oncogene. | Q48322818 | ||
| Changes in gene expression during progression of ovarian carcinoma | Q49222374 | ||
| Examination of oncogene amplification by genomic DNA microarray in hepatocellular carcinomas: comparison with comparative genomic hybridization analysis. | Q53394866 | ||
| Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. | Q53479014 | ||
| Evidence for non-covalent clusters of the c-met proto-oncogene product | Q54269961 | ||
| Differential regulation of axonal growth and neuromuscular junction assembly by HGF/c-Met signaling. | Q54295790 | ||
| Targeting the c-Met/FZD8 signaling axis eliminates patient-derived cancer stem-like cells in head and neck squamous carcinomas. | Q54315132 | ||
| Purification and biological characterization of human hepatopoietin A, a polypeptide growth factor for hepatocytes. | Q54351298 | ||
| Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells. | Q54391771 | ||
| Hepatocyte growth factor receptor, c-Met, in human embryo salivary glands. An immunohistochemical study. | Q54685062 | ||
| MET Y1253D-activating point mutation and development of distant metastasis in advanced head and neck cancers. | Q54729777 | ||
| Biological Activation of pro-HGF (Hepatocyte Growth Factor) by Urokinase Is Controlled by a Stoichiometric Reaction | Q57281116 | ||
| Only a Subset of Met-Activated Pathways Are Required to Sustain Oncogene Addiction | Q58164795 | ||
| Abstract 1889: Smad4 inactivation correlates with EMT and cetuximab resistance in head and neck squamous cell carcinoma | Q59089010 | ||
| A role for HGF/SF in neural induction and its expression in Hensen's node during gastrulation | Q59971496 | ||
| Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats | Q60034429 | ||
| Structure and biological property of fibroblast-derived tumor cytotoxic factor (F-TCF) | Q67929913 | ||
| The human met oncogene is a member of the tyrosine kinase family | Q68241918 | ||
| A study of an in vitro model for invasion of oral squamous cell carcinoma | Q69418700 | ||
| Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas | Q71061803 | ||
| Expression of Met protein in thyroid tumours | Q71870884 | ||
| Expression and localization of hepatocyte growth factor in rat submandibular gland | Q72146134 | ||
| The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit | Q72560868 | ||
| Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer | Q72571222 | ||
| Hepatocyte growth factor promotes motor neuron survival and synergizes with ciliary neurotrophic factor | Q73067636 | ||
| Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas | Q73586595 | ||
| Staging of head and neck squamous cell carcinoma using the MET oncogene product as marker of tumor cells in lymph node metastases | Q73911408 | ||
| u-PA and c-MET mRNA expression is co-ordinately enhanced while hepatocyte growth factor mRNA is down-regulated in human hepatocellular carcinoma | Q74108509 | ||
| Overexpression of scatter factor and its receptor (c-met) in oral squamous cell carcinoma | Q77303734 | ||
| Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer | Q77555522 | ||
| Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas | Q77931840 | ||
| Purification and characterization of hepatocyte growth factor from injured liver of carbon tetrachloride-treated rats | Q28567221 | ||
| Contact inhibition of hepatocyte growth regulated by functional association of the c-Met/hepatocyte growth factor receptor and LAR protein-tyrosine phosphatase | Q28577402 | ||
| The mutational landscape of head and neck squamous cell carcinoma | Q29614654 | ||
| Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies | Q29615606 | ||
| Wnt activity defines colon cancer stem cells and is regulated by the microenvironment | Q29618024 | ||
| Functions of cell surface heparan sulfate proteoglycans | Q29618521 | ||
| TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia | Q29618875 | ||
| The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma | Q30494514 | ||
| Tumor cytotoxic factor/hepatocyte growth factor from human fibroblasts: cloning of its cDNA, purification and characterization of recombinant protein | Q33324580 | ||
| Scatter factor from human embryonic lung fibroblasts is probably identical to hepatocyte growth factor | Q33324581 | ||
| Platinum-based chemotherapy plus cetuximab in head and neck cancer | Q33381094 | ||
| Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival | Q33515519 | ||
| Foretinib Enhances the Radiosensitivity in Esophageal Squamous Cell Carcinoma by Inhibiting Phosphorylation of c-Met | Q33702320 | ||
| Deduced primary structure of rat hepatocyte growth factor and expression of the mRNA in rat tissues | Q33842687 | ||
| Hepatocyte growth factor promotes lymphatic vessel formation and function | Q33919993 | ||
| Chemically oversulfated glycosaminoglycans are potent modulators of contact system activation and different cell signaling pathways | Q34003880 | ||
| Clinicopathological predictors of lymphatic metastasis in HNSCC: implications for molecular mechanisms of metastatic disease | Q34091198 | ||
| Characterization of the rearranged tpr-met oncogene breakpoint | Q34191799 | ||
| Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck | Q34287207 | ||
| Dimerization mediated through a leucine zipper activates the oncogenic potential of the met receptor tyrosine kinase | Q34358610 | ||
| Proteoglycans: pericellular and cell surface multireceptors that integrate external stimuli in the mammary gland | Q34362776 | ||
| Interaction with the phosphotyrosine binding domain/phosphotyrosine interacting domain of SHC is required for the transforming activity of the FLT4/VEGFR3 receptor tyrosine kinase | Q34384347 | ||
| The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus | Q34407347 | ||
| Detection of MET oncogene/hepatocyte growth factor receptor in lymph node metastases from head and neck squamous cell carcinomas. | Q34419289 | ||
| Common critical pathways in embryogenesis and cancer | Q34535747 | ||
| Oncogenic activation of the Met receptor tyrosine kinase fusion protein, Tpr-Met, involves exclusion from the endocytic degradative pathway. | Q34632213 | ||
| Transitions between epithelial and mesenchymal states in development and disease | Q34761972 | ||
| Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab | Q35001415 | ||
| Stage-dependent regulation of mammary ductal branching by heparan sulfate and HGF-cMet signaling. | Q35056355 | ||
| Novel role for endogenous hepatocyte growth factor in the pathogenesis of intracranial aneurysms. | Q35079472 | ||
| Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells | Q35110418 | ||
| HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer | Q35174872 | ||
| Expression of Met/hepatocyte growth factor receptor gene and malignant behavior of musculoskeletal tumors. | Q35782214 | ||
| Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma | Q35796063 | ||
| CD44 is required for two consecutive steps in HGF/c-Met signaling. | Q35805198 | ||
| Expression of c-Met and heparan-sulfate proteoglycan forms of CD44 in colorectal cancer | Q35829554 | ||
| Growth factor expression mediates resistance to EGFR inhibitors in head and neck squamous cell carcinomas. | Q38777541 | ||
| Mitigation of Tumor-Associated Fibroblast-Facilitated Head and Neck Cancer Progression With Anti-Hepatocyte Growth Factor Antibody Ficlatuzumab. | Q38821826 | ||
| Crizotinib Fails to Enhance the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Xenografts | Q38824660 | ||
| Areca nut contributes to oral malignancy through facilitating the conversion of cancer stem cells | Q38862494 | ||
| Cancer Statistics, 2017. | Q39038674 | ||
| A fibroblast-derived tumor cytotoxic factor/F-TCF(hepatocyte growth factor/HGF) has multiple functions in vitro | Q39101294 | ||
| Identity of a tumor cytotoxic factor from human fibroblasts and hepatocyte growth factor | Q39101924 | ||
| Discovery of novel 4-(2-fluorophenoxy)quinoline derivatives bearing 4-oxo-1,4-dihydrocinnoline-3-carboxamide moiety as c-Met kinase inhibitors | Q39158608 | ||
| A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3. | Q39473718 | ||
| Beta4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorage-independent growth | Q39750624 | ||
| E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models | Q39787136 | ||
| Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members | Q40009294 | ||
| Mature hepatocyte growth factor/scatter factor on the surface of human granulocytes is released by a mechanism involving activated factor Xa. | Q40278091 | ||
| The potential lymphangiogenic effects of hepatocyte growth factor/scatter factor in vitro and in vivo | Q40377167 | ||
| Purification and partial characterization of hepatocyte growth factor from plasma of a patient with fulminant hepatic failure | Q40510836 | ||
| Oligomerization-induced Modulation of TPR-MET Tyrosine Kinase Activity | Q40652658 | ||
| Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis | Q40755904 | ||
| Characterization of a functional relationship between hepatocyte growth factor and mouse bone marrow-derived mast cells | Q40935169 | ||
| Engineered mutants of HGF/SF with reduced binding to heparan sulphate proteoglycans, decreased clearance and enhanced activity in vivo | Q41052630 | ||
| Transient and locally restricted expression of the ros1 protooncogene during mouse development | Q41083296 | ||
| Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET | Q41152225 | ||
| Overexpression of the met/HGF receptor in renal cell carcinomas | Q41190769 | ||
| The receptor encoded by the human C-MET oncogene is expressed in testicular tissue and on human spermatozoa | Q41241902 | ||
| Hepatocyte growth factor stimulates extensive development of branching duct-like structures by cloned mammary gland epithelial cells | Q41375138 | ||
| Hepatocyte growth factor/scatter factor stimulates the Ras-guanine nucleotide exchanger. | Q41554332 | ||
| Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth | Q41596252 | ||
| Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor | Q41656206 | ||
| Hepatocyte growth factor has potent anti-proliferative activity in various tumor cell lines | Q41660621 | ||
| Comparison of biological and immunochemical properties indicates that scatter factor and hepatocyte growth factor are indistinguishable | Q41666984 | ||
| c-met is amplified but not mutated in a cell line with an activated met tyrosine kinase | Q41690281 | ||
| Met-induced JNK activation is mediated by the adapter protein Crk and correlates with the Gab1 - Crk signaling complex formation | Q41711750 | ||
| HGF upregulation contributes to angiogenesis in mice with keratinocyte-specific Smad2 deletion | Q41834933 | ||
| Hepatocyte growth factor/scatter factor can induce angiogenesis independently of vascular endothelial growth factor | Q42435592 | ||
| Silencing Met receptor tyrosine kinase signaling decreased oral tumor growth and increased survival of nude mice. | Q42735478 | ||
| Reconstitution of mammary gland development in vitro: requirement of c-met and c-erbB2 signaling for branching and alveolar morphogenesis | Q42796653 | ||
| Tyrosines1234-1235 are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor). | Q42802867 | ||
| Scatter factor is a fibroblast-derived modulator of epithelial cell mobility | Q42807925 | ||
| Mechanism of met oncogene activation | Q42811433 | ||
| Tyrosine kinase receptor indistinguishable from the c-met protein | Q42814654 | ||
| Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck | Q43164702 | ||
| Down-regulation of MET, the receptor for hepatocyte growth factor. | Q43649368 | ||
| Hepatocyte growth factor/scatter factor is an axonal chemoattractant and a neurotrophic factor for spinal motor neurons | Q43819365 | ||
| An epithelial scatter factor released by embryo fibroblasts. | Q43820611 | ||
| MET receptor is overexpressed but not mutated in oral squamous cell carcinomas. | Q43827034 | ||
| Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma | Q43865519 | ||
| Presence of a mobilizable intracellular pool of hepatocyte growth factor in human polymorphonuclear neutrophils | Q43945200 | ||
| Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas | Q44363232 | ||
| Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies | Q45246419 | ||
| Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas | Q45345804 | ||
| Molecular cloning of a new transforming gene from a chemically transformed human cell line. | Q45345810 | ||
| Do morphogen gradients arise by diffusion? | Q46502677 | ||
| Hepatocyte growth factor/scatter factor induces tyrosine phosphorylation of focal adhesion kinase (p125FAK) and promotes migration and invasion by oral squamous cell carcinoma cells | Q46722158 | ||
| Control of photoreceptor cell fate by the sevenless protein requires a functional tyrosine kinase domain | Q47072621 | ||
| Overexpression of stromelysin-3, BM-40/SPARC, and MET genes in human esophageal carcinoma: implications for prognosis. | Q47975607 | ||
| Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer | Q36005545 | ||
| Transfer of motogenic and invasive response to scatter factor/hepatocyte growth factor by transfection of human MET protooncogene | Q36065558 | ||
| Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells | Q36223889 | ||
| Sequential requirement of hepatocyte growth factor and neuregulin in the morphogenesis and differentiation of the mammary gland | Q36236069 | ||
| Heparin induces dimerization and confers proliferative activity onto the hepatocyte growth factor antagonists NK1 and NK2. | Q36236835 | ||
| Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer | Q36286731 | ||
| Expression of c-Met Is Different along the Location and Associated with Lymph Node Metastasis of Head and Neck Carcinoma | Q36518737 | ||
| c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met | Q36545205 | ||
| Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network | Q36557528 | ||
| Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. | Q36660533 | ||
| The tyrosine kinase encoded by the MET proto-oncogene is activated by autophosphorylation | Q36687206 | ||
| Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. | Q36689648 | ||
| Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor | Q36705281 | ||
| A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met | Q36777999 | ||
| Receptor trafficking controls weak signal delivery: a strategy used by c-Met for STAT3 nuclear accumulation. | Q36860354 | ||
| Targeting HER proteins in cancer therapy and the role of the non-target HER3. | Q36898642 | ||
| Heparanase 2 Attenuates Head and Neck Tumor Vascularity and Growth | Q36917969 | ||
| Ten years of progress in head and neck cancers | Q37002445 | ||
| Hepatocyte growth factor--scatter factor: mitogen, motogen, and met | Q37105518 | ||
| Cancer as an overhealing wound: an old hypothesis revisited | Q37217254 | ||
| A functional domain in the heavy chain of scatter factor/hepatocyte growth factor binds the c-Met receptor and induces cell dissociation but not mitogenesis | Q37329953 | ||
| Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary cultures | Q37397472 | ||
| Alteration status and prognostic value of MET in head and neck squamous cell carcinoma | Q37514050 | ||
| Evidence for the identity of human scatter factor and human hepatocyte growth factor | Q37574028 | ||
| MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy | Q37597858 | ||
| Mechanisms of hepatocyte growth factor activation in cancer tissues | Q38255480 | ||
| Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx | Q38450015 | ||
| Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma | Q38466547 | ||
| Cellular and molecular mechanisms of HGF/Met in the cardiovascular system. | Q38631649 | ||
| Oleic acid-induced ANGPTL4 enhances head and neck squamous cell carcinoma anoikis resistance and metastasis via up-regulation of fibronectin | Q38730122 | ||
| Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment | Q38761147 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 12 | |
| P577 | publication date | 2017-12-12 | |
| P1433 | published in | Cancers | Q27722963 |
| P1476 | title | Activated HGF-c-Met Axis in Head and Neck Cancer | |
| P478 | volume | 9 |
| Q91902169 | Clinical update on head and neck cancer: molecular biology and ongoing challenges |
| Q89823731 | Crosstalk Mechanisms Between HGF/c-Met Axis and ncRNAs in Malignancy |
| Q60920855 | HGF/c-MET Signaling in Melanocytes and Melanoma |
| Q58574781 | HGF/c-MET: A Promising Therapeutic Target in the Digestive System Cancers |
| Q92531037 | Hepatocyte Growth Factor Receptor overexpression predicts reduced survival but its targeting is not effective in unselected HNSCC patients |
| Q64238086 | Novel genetic alterations and their impact on target therapy response in head and neck squamous cell carcinoma |
| Q97074416 | Structural and Functional Insight Into the Glycosylation Impact Upon the HGF/c-Met Signaling Pathway |
| Q90620359 | Targeting cancer stem cells in squamous cell carcinoma |
| Q92661565 | The Influence of Met Receptor Level on HGF-Induced Glycolytic Reprogramming in Head and Neck Squamous Cell Carcinoma |
| Q61818143 | c-Src Recruitment is Involved in c-MET-Mediated Malignant Behaviour of NT2D1 Non-Seminoma Cells |
Search more.